JP7336805B2 - フルオロ置換ポルフィリン化合物、該化合物を含む医薬組成物、並びに該化合物を調製及び使用する方法 - Google Patents

フルオロ置換ポルフィリン化合物、該化合物を含む医薬組成物、並びに該化合物を調製及び使用する方法 Download PDF

Info

Publication number
JP7336805B2
JP7336805B2 JP2020517334A JP2020517334A JP7336805B2 JP 7336805 B2 JP7336805 B2 JP 7336805B2 JP 2020517334 A JP2020517334 A JP 2020517334A JP 2020517334 A JP2020517334 A JP 2020517334A JP 7336805 B2 JP7336805 B2 JP 7336805B2
Authority
JP
Japan
Prior art keywords
subject
administered
radiation
chemotherapy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536055A5 (enExample
JP2020536055A (ja
Inventor
バティニック－ハベルレ，イネス
トブマシャン，アルタック
スパソジェヴィック，アイヴァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2020536055A publication Critical patent/JP2020536055A/ja
Publication of JP2020536055A5 publication Critical patent/JP2020536055A5/ja
Application granted granted Critical
Publication of JP7336805B2 publication Critical patent/JP7336805B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1094—Shielding, protecting against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020517334A 2017-09-29 2018-09-26 フルオロ置換ポルフィリン化合物、該化合物を含む医薬組成物、並びに該化合物を調製及び使用する方法 Active JP7336805B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762565436P 2017-09-29 2017-09-29
US62/565,436 2017-09-29
PCT/US2018/052826 WO2019067523A1 (en) 2017-09-29 2018-09-26 FLUOROSUBSTITUTED PORPHYRIN COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS OF PREPARATION AND USE THEREOF

Publications (3)

Publication Number Publication Date
JP2020536055A JP2020536055A (ja) 2020-12-10
JP2020536055A5 JP2020536055A5 (enExample) 2021-11-11
JP7336805B2 true JP7336805B2 (ja) 2023-09-01

Family

ID=65903171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517334A Active JP7336805B2 (ja) 2017-09-29 2018-09-26 フルオロ置換ポルフィリン化合物、該化合物を含む医薬組成物、並びに該化合物を調製及び使用する方法

Country Status (8)

Country Link
US (1) US11344574B2 (enExample)
EP (1) EP3687551A4 (enExample)
JP (1) JP7336805B2 (enExample)
KR (1) KR102699638B1 (enExample)
CN (1) CN111417400B (enExample)
CA (1) CA3076008A1 (enExample)
MX (1) MX2020002958A (enExample)
WO (1) WO2019067523A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394244B (es) 2017-04-04 2025-03-24 Biomimetix Jv Llc Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia
EP3687551A4 (en) 2017-09-29 2021-06-23 Duke University FLUORUSUBSTITUTED PORPHYRINE COMPOUNDS, THESE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE
CN115192705B (zh) * 2021-04-13 2023-10-13 中国科学院化学研究所 一种两性离子共价有机聚合物/二氧化钛纳米复合材料及其制备方法和应用
CN116333037A (zh) * 2021-12-17 2023-06-27 化学与精细化工广东省实验室 含巯基肽与氟代卟啉类偶联用作生物探针

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080881A1 (en) 2009-01-07 2010-07-15 Duke University Substituted porphyrins
JP2012506425A (ja) 2008-10-24 2012-03-15 ウニベルシダージ デ コインブラ クロリンの製造方法、及びその医薬としての使用
JP2020502280A (ja) 2016-12-20 2020-01-23 デューク ユニバーシティＤｕｋｅ Ｕｎｉｖｅｒｓｉｔｙ 置換ポルフィリン医薬化合物及び組成物を製造する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2520735B2 (ja) * 1988-07-14 1996-07-31 東洋薄荷工業株式会社 ポルフィリン誘導体
EP1045851B1 (en) 1997-11-03 2003-04-23 Duke University Substituted porphyrins
JPH11217385A (ja) * 1998-01-30 1999-08-10 Nihon Schering Kk 含フッ素ポルフィリン錯体およびそれを含有する造影剤
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
US20030050297A1 (en) 2001-01-19 2003-03-13 Crapo James D. Cancer therapy
EP1718201B1 (en) 2004-02-09 2016-09-14 Duke University Substituted porphyrins
BRPI0509359A (pt) * 2004-03-29 2007-09-04 Inotek Pharmaceuticals Corp compostos de porfirina substituìda por piridila e métodos de empregos destes
CN101235036A (zh) 2007-02-02 2008-08-06 济南赛文医药技术有限公司 一类卟啉衍生物及其作为小分子抗氧化剂的应用
WO2015034778A1 (en) 2013-09-03 2015-03-12 Biomimetix J.V., Llc Methods of treating erectile dysfunction
US10080759B2 (en) 2014-01-22 2018-09-25 Duke University Methods of treating pruritus
US10064871B2 (en) 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
WO2018237249A1 (en) 2017-06-22 2018-12-27 Biomimetix Jv, Llc Methods, compositions, and kits for treating inflammatory skin conditions
EP3687551A4 (en) 2017-09-29 2021-06-23 Duke University FLUORUSUBSTITUTED PORPHYRINE COMPOUNDS, THESE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506425A (ja) 2008-10-24 2012-03-15 ウニベルシダージ デ コインブラ クロリンの製造方法、及びその医薬としての使用
WO2010080881A1 (en) 2009-01-07 2010-07-15 Duke University Substituted porphyrins
JP2020502280A (ja) 2016-12-20 2020-01-23 デューク ユニバーシティＤｕｋｅ Ｕｎｉｖｅｒｓｉｔｙ 置換ポルフィリン医薬化合物及び組成物を製造する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Artak TOVMASYAN et al.，Anticancer therapeutic potential of Mn porphyrin/ascorbate system，Free Radical Biology & Medicine，2015年，vol.89，p.1231-1247
上瀧 萌など，ビタミンＣの抗がん剤としての有効性－がん細胞におけるアスコルビン酸の毒性作用機序－，ビタミン，2013年，87(3)，p.159-163

Also Published As

Publication number Publication date
KR102699638B1 (ko) 2024-08-28
CN111417400B (zh) 2022-12-02
CN111417400A (zh) 2020-07-14
US20210361702A1 (en) 2021-11-25
MX2020002958A (es) 2020-08-20
EP3687551A1 (en) 2020-08-05
EP3687551A4 (en) 2021-06-23
US11344574B2 (en) 2022-05-31
CA3076008A1 (en) 2019-04-04
JP2020536055A (ja) 2020-12-10
WO2019067523A1 (en) 2019-04-04
KR20200079237A (ko) 2020-07-02

Similar Documents

Publication Publication Date Title
JP7336805B2 (ja) フルオロ置換ポルフィリン化合物、該化合物を含む医薬組成物、並びに該化合物を調製及び使用する方法
RU2000102359A (ru) Фармацевтическая композиция, обладающая улучшенным противораковым действием и/или сниженными побочными эффектами, содержащая противораковый агент и производное гидроксамовой кислоты
JP2025516821A (ja) 安定性の高い重金属除去組成物およびその用途、剤形、製造方法
EP0781554A1 (en) Hydroxyl radical scavenger
HUE027711T2 (en) An aqueous formulation of improved stability of (E) -4-carboxystyril-4-chlorobenzylsulfone
EP2643301B1 (fr) Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
EP4349341A1 (en) Pharmaceutical preparation for preventing or treating pulmonary fibrosis
CN104718190B (zh) 用于光动力疗法的吡啶酮化合物
US20110275606A1 (en) Substituted porphyrins
JP5908485B2 (ja) 神経変性疾患のポルフィリン治療
ES2355784A1 (es) Complejos metalicos mimeticos de sod.
EP3914359B1 (en) Triphenylphosphonium-tethered salicylamine derivatives
CN112716954A (zh) 氯化两面针碱的药物新用途
CN111320662A (zh) 一类n-苄基取代的二脒那秦衍生物及其药物用途
KR20210046115A (ko) 니아신 유도체 및 이를 함유하는 약학 조성물
US11236056B2 (en) Small molecules and methods of reducing injuries caused by radiation or chemicals
CN111960978A (zh) 一种具有神经保护活性的s-烯丙基-l-半胱氨酸取代酪醇衍生物合成方法及其应用
JP5147825B2 (ja) アンペロプシンの不飽和ナトリウム塩の製剤及びその応用
CN118084819A (zh) 噻唑类衍生物及其在治疗白血病中的应用
HK40054304A (en) Triphenylphosphonium-tethered salicylamine derivatives
HK40054304B (en) Triphenylphosphonium-tethered salicylamine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230815

R150 Certificate of patent or registration of utility model

Ref document number: 7336805

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150